Dow Jones
39.872,99 +66,22 (+0,17%) Nasdaq
16.832,62 +37,75 (+0,22%) Nikkei 225
38.704,78 -242,15 (-0,62%) EUR/USD
1,0859 0,0000 (-0,00%) Bitcoin EUR
64.426,25 -1.164,30 (-1,78%) CMC Crypto 200
1.475,86 -12,69 (-0,85%)
Takeda Pharmaceutical Co Ltd (TKD.BE)
| Chiusura precedente | 24,43 |
| Aperto | 24,07 |
| Denaro | 24,22 x 0 |
| Domanda | 24,43 x 0 |
| Min-Max giorno | 24,07 - 24,07 |
| Intervallo di 52 settimane | 24,07 - 30,68 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 31 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
- GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results
